Cardiorenal syndrome: limits of heart failure therapy

• Published in: Herz Vol. 38; no. 6; pp. 569 - 577
• Main Authors: Großekettler, L, Schmack, B, Schwenger, V
• Format: Journal Article
• Language: English; German
• Published: Germany 01-09-2013
• Subjects: Cardio-Renal Syndrome - diagnosis; Cardio-Renal Syndrome - mortality; Cardio-Renal Syndrome - therapy; Cardiotonic Agents - therapeutic use; Combined Modality Therapy; Extracorporeal Circulation - mortality; Humans; Prevalence; Renal Replacement Therapy - mortality; Risk Factors; Treatment Outcome
• ISSN: 0340-9937; 1615-6692
• DOI: 10.1007/s00059-013-3847-6

The cardiorenal syndrome is an interdisciplinary challenge with increasing health economic relevance. Renal failure is a strong predictor for mortality in patients with severe congestive heart failure (CHF) and CHF is one of the fastest increasing morbidities in western countries. For successful therapy a close cooperation between cardiology und nephrology is required. Moreover, a good compliance of the patient is needed to improve symptoms and to reduce the frequency of cardiac decompensation. A broad cardiological and nephrological evaluation and consideration of optimal conservative options according to national and international guidelines are essential. However, a renal replacement therapy might be helpful in patients with refractory heart failure even if they are not dialysis-dependent. In cases of acute heart and renal failure an intensive care management might be necessary to reduce volume overload with the help of extracorporeal ultrafiltration or a dialysis modality. Nevertheless, in cases of chronic refractory CHF peritoneal dialysis should be preferred. The first analysis of the registry of the German Society of Nephrology (http://www.herz-niere.de) confirmed that there is a benefit for health-related quality of life in chronic CHF patients treated with peritoneal dialysis.